EP0097648A4 - Sang entier synthetique et son procede de production. - Google Patents

Sang entier synthetique et son procede de production.

Info

Publication number
EP0097648A4
EP0097648A4 EP19820902044 EP82902044A EP0097648A4 EP 0097648 A4 EP0097648 A4 EP 0097648A4 EP 19820902044 EP19820902044 EP 19820902044 EP 82902044 A EP82902044 A EP 82902044A EP 0097648 A4 EP0097648 A4 EP 0097648A4
Authority
EP
European Patent Office
Prior art keywords
phase
whole blood
coacervate
blood
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19820902044
Other languages
German (de)
English (en)
Other versions
EP0097648A1 (fr
Inventor
Charles S Ecanow
Bernard Ecanow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neomed Corp
Original Assignee
Neomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomed Inc filed Critical Neomed Inc
Publication of EP0097648A1 publication Critical patent/EP0097648A1/fr
Publication of EP0097648A4 publication Critical patent/EP0097648A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00—Photosensitive materials
    • G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047—Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471—Isoelectric point of gelatine

Definitions

  • This inyention relates to a synthetic whole blood for use as a substitute for whole natural mara mallian blood and a method of preparing same.
  • the present invention relates to a method of making a synthetic whole blood which comprises the steps of: preparing a solution by dispersing from 5 to 25% weight to volume of albumin in water contain ing 0.9% weight to volume sodium chloride, 1 to 5% weight to volume urea and 0.1 to 10% weight to volume of a phospholipid; storing the solution, undisturbed at 4 degrees C.
  • It also relates to a method of making a synthetic whole blood which comprises the steps of mixing thoroughly 5 to 15% weight to volume of gelatin powder with 5 to 15% weight to volume of acacia which has been dispersed in water; storing the solution undisturbed at 10 degrees C. for 24 hours to produce a two phase coacervate system; adjusting the pH of said system to a value within the range of 6.8 to 7.4 preferably by the addition of sodium hydroxide; adding such amount of sodium chloride to said system as will make it isotonic with whole human blood; emulsifying the two phase coacervate system to produce droplets ranging in size from 2 to 9 microns.
  • the semi-prepared synthetic whole blood product described in the paragraph above including at least 0.05 ml. of a non-polar solvent or a semi-non-polar solvent per liter of semi-prepared blood product. It also relates to a synthectic whole blood comprising 95-75% weight to volume of the semi-prepared synthetic whole blood product described in either of the two paragraphs immediately above, 5-25% weight to volume of water, and a small amount of NaCl, said synthetic whole blood thereby being isotonic with natural whole human blood.
  • a semi-prepared synthetic whole blood product comprising 4.25 to 14.25% weight to volume acacia in H 2 O, and 5 to 15% weight to volume gelatin, said components forming coacervate system having a coacervate phase and an equilibrium bulk water phase; and also alsynthetic whole blood comprising this semi-prepared synthetic whole blood product, and a small amount of NaCl, or H-,0, said synthetic whole blood thereby being isotonic with natural whole human blood. From a physicochemical point of view, whole mammalian blood in the body exists and functions as a two phase coacervate system.
  • a coacervate system is a polyphasic physical chemical system having two phases, each phase, consisting chiefly of liquid water and each phase, by reason of its thermodynamic state, being insoluble in the other phase.
  • Erythrocytes largely composed of water comprise the relatively non polar coacervate phase of the coacervate system referred to above.
  • Plasma which also consists primarily of water constitutes the bulk water, relatively polar aqueous phase of the system.
  • the two phases normally exist in equilibrium with respect to dissolved molecules and electrolytes.
  • any change that significantly affects the components or their concentration of the coacervate system will dis turb the normal steady state with consequent physiological effect.
  • alteration of the electrolyte content of the plasma ie. change in the relatively polar water state
  • destruction of the erythrocytes ie. change in the non polar coacervate phase
  • This inyention comprises safe and effective substitutes for whole, natural blood and methods of manufacture thereof.
  • the claimed invention makes use of the concepts and process of coacervation.
  • the claimed process of manufacture produces a two phase coacervate system substantially identical to the two phase physico chemical system of whole natural blood; ie: a non polar coacervate phase insoluble in and in equilibrium with an associated polar bulk water equilibrium phase.
  • the coacervate phase comprises from 1 to 99% of the two phase system.
  • the bulk water equilibrium phase con stitutes from 1 to 99% of the coacervate system.
  • the coacervate phase substantially possesses the physiological and physicochemical properties of naturally occurring hematocrit while the bulk water equilibrium phase is substantially the physiological and physicochemical equivalent of naturally occurring blood plasma.
  • the two phase coacervate system can be infused into a recipient and will function as whole blood.
  • the two phase coacervate system is brought into even closer functional equivalence with whole, natural blood during the process of manufacture, by the addition of appropriate proteins, electrolytes, a sterol, and if desired, stroma free hemoglobin.
  • the coacervate phase can be safely introduced intravenously to either carry out or enhance the physiological functions of hematocrit. It can transport and transfer oxygen and carbon dioxide much as naturally occurring erythrcc ytes do.
  • the introduced hematocrit substitute ie; coacervate phase of the two phase coacervate system
  • coacervate phase of the two phase coacervate system will not adversely affect the per cent of the recipient's hematocrit.
  • it when it is infused, it will disperse in the blood plasma of the recipient, thereby contributing to the two phase physicochemical system of the whole blood to which, it has been added.
  • the physico chemical characteristics of the coacervate phase render it sensitive and reactive to both the physiological state and physiological changes in the recipient's blood.
  • the claimed hematocrit substitute can readily enter and pass through, the major blood vessels, capil laries and the microcirculation.
  • the emulsified form of the two phase coacervate system is infused intravenously. If the preferred method is followed, the infused syn thetic whole blood will be comprised of the two phase coacervate system and appropriate additives, the combination of which, will have been emulsified prior to use.
  • the claimed composition can not only carry out vital functions of normal whole blood but in addition can be safely used in a wide variety of treatment procedures including the establishment and maintenance of extra corporeal circulation. By reason of its physicochemical procedures, the claimed synthetic whole blood will circulate readily within the entire vascular system.
  • the claimed composition can establish., re-establish, and/or maintain normal osmotic pressures, transport and transfer physiological gases, can carry nutrients, drug dosage forms and various physiological entities over extended periods of time without loss of stability.
  • the transport characteristics of the claimed compositions of matter enable them to serve as a safe and reliable vehicle in hyperalimentation procedures.
  • enzyme systems When it is desirable to introduce enzyme systems into the body, such systems can be added to the coacervate phase of this invention and infused through conventional intravenous methods. Enzyme systems introduced through these compositions of matter will perform their normal physiological functions.
  • stroma free hemoglobin may be added to the coacervate phase or to th.e emulsified coacervate system. Such addition does not affect the stability or the physiological capabilities of the claimed compositions.
  • the disclosed synthetic whole blood can be rendered free of foreign proteins and other elements which contribute to the adverse reactions associated with transfusion of whole human blood. Further, because this invention possesses universal donor characteristics, no blood typing is necessary prior to infusion of this composition of matter. An additional important advantage of the claimed whole blood substitute over whole human blood is that it can be readily modified to meet many of the specific requirements of specific medical and surqical treatment procedures.
  • compositions When infused into humans, the compositions may be at ambient temperature and preferably should be at a temperature that approximates 98.6 degrees F (37oC).
  • Either of two groups of component ingredients can be used in the preparation of the claimed compositions of matter.
  • the groups are of substantially equal utility in producing the necessary two phase coacervate system. Irrespective of the group of ingredients selected for use, the fundamental manufacturing step remains the same; i.e. a process of coacervation constitutes the method by which the component ingredients are combined.
  • the two phase coacervate system is to be prepared from the group of ingredients herein referred to as Group A, the preferred ingredients will include al bumin, sodium chloride, urea, lecithin, and distilled water. If the coacervate system is to be manufactured using ingredients comprising the group herein referred to as Group B, the preferred ingredients will consist of acacia USP, gelatin solution, sterile water and IN hydrochloric acid. If the coacervate system is to be manufactured using ingredients herein referred to as Group C, the preferred ingredients will be those of Group A and additionally a non-polar solvent or a semi non-polar solvent.
  • the additives used to bring the composition into closer physiological approximation with whole mammalian blood are the same.
  • the. additives comprise the following: cholesterol, calcium chloride, potassium chloride, electrolytes and stroma free hemoglobin.
  • Certain treatment regimens may make the addition of mucopolysaccarides, glycoproteins, proteins, enzymes and other molecules such as heparin desirable.
  • coacervated structured, water-insoluble droplets are formed. Under the conditions of the manu- facture of this invention, these droplets coalesce to form the coacervate phase of the two phase coacervate system.
  • This system can be readily emulsified to form droplets of any desired size. In this invention, the preferred size can range from 2 to 9 microns.
  • the prior art contains no reference which suggests or hints at a method of manufacture of a synthetic whole blood based upon the process of coacervation; nor does it hint at or suggest the composition of a two phase coacervate system which will function virtually as whole blood. Further, the prior art makes no mention of a substitute for hematocrit comprised of the coacervate phase of the claimed coacervate system.
  • the two phases may be separated.
  • the two component phases are separated after the ingredients described below haye been mixed but before emulsification of the coacervate system and addition of the incorporated additives.
  • the coacervate system may now be separated into its two component phases, or alternatively, emulsified to produce droplets ranging in size from 2 to 9 microns.
  • the composition in its emulsified form, can be used as a synthetic whole blood.
  • the separated co acervate phase of the two phase system can be used as a substitute for hematocrit.
  • emul sification of the two phase coaceryate system is delayed until the procedures described immediately below, are completed; add such, amount of cholesterol as will result in a 0.1 to 2% weight to volume concentration of cholesterol in the said system.
  • the resulting composition comprises the claimed synthetic whole blood.
  • the claimed synthetic whole blood should be at temperatures approximating normal human temperatures Ci.e. 98.7°F which, is 37°C.). Storage of the claimed synthetic whole blood, if necessary, should be at 4 to
  • the two phases of the coacervate system may be separated, for instance, by means of a separatory funnel prior to emulsification.
  • the separated coacervate phase is useful as a substitute for hematocrit.
  • Five to ten per cent weight to volume of stroma free hemoglobin optionally may be added to the separated coacervate phase, or optionally may be added, prior to the emulsification step, to the two phase coacervate system, .Also, stroma free hemoglobin optionally may be added, prior to the emulsification step, to the two phase coacervate system containing the additive ingredients described immediately above. Addition of stroma free hemoglobin will enhance the intrinsic oxygen transport capability of both, compositions of matter.
  • a phospholipid is included as a necessary component.
  • Lecithin is the preferred phospholipid. Any of the following or mixtures thereof can be used in combination with or in place of lecithin: cephalin, isolecithin, sphinomyelin, phosphatidyl serine, phosphatidyl inositol, phosphotidyl choline and phosphatidic acid.
  • This invention also teaches a second method of making a synthetic whole blood using the ingredients described in this, document as comprising Group B.
  • This method is also based on a process of coacervation.
  • the preferred procedure comprises the following steps: 5 to 15% weight to volume of gelatin powder is thoroughly mixed with. 5 to 15% weight to volume of acacia which has been dispersed in sterile water. The solution is then stored undisturbed at 10 degrees. C. for 24 hours, after which, it is remoyed from refrigeration. Ordinarily, this step will produce the required two phase coacervate system. If the said system does not result IN hydrochloric acid may be added dropwise to the solution until separation of the two phases occurs, indicating forma- tion of the coacervate system.
  • Said system then is adjusted to a pH in the range of 6.8 to 7.4 by adding sodium hydroxide. If the two phase coacervate system has formed during the 24 hour period of refrigerated storage, then, as indicated above hydrochloric acid is not added; however, if th.e pH. of the said system is not in the range of 6.8 to 7.4. it is made so by adding sodium hydroxide.
  • the coacervate system is made isotonic with whole mammalian blood by adding sterile water and/or sodium chloride. The system may then be emulsified to produce droplets ranging in size from 2 to 9. microns. As such, it is useful as a whole blood substitute. Alternatively, the phases are separated; the coacervate phase can be used as a substitute for hematocrit. If not infused, the compositions may be stored at 4 to 10 degrees C.
  • the emulsifying step occurs after the following sequence of steps: To the two phase coacervate system described above, such amount of cholesterol is added as will result in a 1% weight to volume concentration of cholesterol in said system. Next, calcium chloride powder. is added to a concentration of from 3 to 5 mg.% and potassium chloride to a concentration of.1 to 3 mg.%. Th.e preparation is then titrated to a pH within the range of 6.8 to 7.4 by adding the appropriate amount of sodium hydroxide; the pH of normal whole human blbod is preferred. Sterile water and sodium chloride isadded as required, to render the coacervate system isotonic with, whole human blood. The system is then mixed vigorously for one hour.
  • the preparation is stored for 24 to 148 hours at 10 degrees C.
  • the preparation is then removed from refrigerated storage and at ambient temperature, emulsified by any of the recognized methods to produce globules ranging in size from 2 to 9. microns.
  • This step completes the preparation of synthetic whole blood using the components of the previously described Group B.
  • the compositions can now be infused at ambient temperature, preferably at normal body temperature, into the recipient or stored at 4 to 10 degrees C.
  • the two phases of the coacervate system are separated prior to emulsification, for instance, by means of a separatory funnel.
  • the coacervate phase of the system is useful as a hematocrit substitute. It can be infused at ambient temperature, preferably at normal body temperature, into a recipient or stored at from 4 to 10 degrees C.
  • stroma free hemoglobin Five to ten percent weight to volume of stroma free hemoglobin can be added to either the separated coacervate phase or, prior to emulsification, to the two phase coacervate system. Such addition will enhance the intrinsic oxygen transport capability of these compositions.
  • Specific treatment regimens can be instrumented through the claimed synthetic whole blood; i.e. hyperalimentation, intravenous drug therapy, etc.
  • the ingredients necessary to any given treatment regimen are added to the coacervate system prior to emulsification.
  • Any number of solvents may be used for Group C compositions.
  • the solvents may be non-polar solvents or semi-non-polar solvents.
  • solvents useful for this purpose butanol, ethyl acetate, dibutanol ketone , glycerol mono-acetate, glycerol di-acetate, glycerol tri-acetate, glycerol dioleate, di-chloromethylene.
  • the preferred solvent is di-chloromethylene.
  • compositions of Group C must be carried out under aseptic conditions. Except for those steps involving refrigeration, all other procedures are performed at ambient temperatures. If it is desired, the compositions may be stored at 4 to 10 degrees C. When infused, the compositions preferably should be at a temperature that approximates normal body temperature. The following is a description of the preferred method of preparing the claimed compositions of Group C.
  • the coacervate system can be separated into its two component phases, or alternatively, the system can be emulsified to produce droplets ranging in size from 2 to 9 microns. If the phases are separated, the coacervate phase can be used as a hematocrit substitute. If the system is emulsified, the composition can be used as a whole mammalian blood substitute. Storage should be at from 4 to 10 degrees C.
  • the preparation is then allowed to reach room temperature.
  • the product is emulsified to produce droplets ranging in size from 2 to 9 microns.
  • the composition that results from these procedures con stitutes the claimed synthetic whole blood of Group C. Storage, if necessary, should be at 4 to 10 degrees C. If it is desired, the two phases of the coacervate system described immediately above may be separated prior to the emulsifying step. If the phases are separated, the separated coacervate phase is useful as a hematocrit substitute.
  • Fiye to ten per cent weight to volume of stroma free hemoglobin can be added as an option, to th.e separated coaceryate phase, or to the coacervate system prior to its emuIsification. In either preparation, the addition of stroma free hemoglobin will enhance the intrinsic oxygen transport capacity of the claimed compositions of matter.
  • Lecithin is the preferred phospholipid in preparing the disclosed compositions of matter.
  • any of the following or mixtures thereof can be used in place of lecithin: isolecithin, sphingomyelin, phosphatidyl serine, phosphatidyl inositol, phosphatidyl choline and phosphatidic acid.
  • Cholesterol is the preferred sterol in the method(s) of manufacture of the claimed compositions of matter. However, any of the following sterols can be used in place of the preferred cholesterol: ergosterol, 7-dehydrocholesterol, ⁇ sitosterol, ⁇ sitosterol, ⁇ sitosterol, campesterol or mixtures thereof.
  • the solution is then mixed vigorously for one hour following which it is stored at a temperature of 10 degrees C. for 148 hours. At the end of this period, the solution will have separated into two distinct layers.
  • the bottom layer comprises the coacervate phase of the two phase coacervate system; the upper layer comprises the equilibrium water phase of the system.
  • the two phases of the system can be separated or emulsified, for the purposes and in the manner described previously.
  • Infusion of the synthetic whole blood into the circulation of the recipient may take place at ambient temperatures and preferably should take place at normal body temperature.
  • the storage of synthetic whole should be at from 4 to 10 degrees C. The same parameters govern the use and storage of the claimed hematocrit substitute.
  • Example 1 This procedure follows Example 1. except that 50 grams of stroma free hemoglobin are added to the coacervate phase and thoroughly swirled in a flat bottom flask to achieve, a uniform dispersion of the added hemoglobin.
  • Example 1 The procedure follows Example 1 except that after the manufacture of the two phase coacervate system is completed, the coacervate phase is separated from its equilibrium water phase by means of a separatory funnel. The separated coacervate phase will function as hematocrit when introduced intravenously.
  • Fiye percent weight to volume of gelatin powder (IEP:8.2) is mixed thoroughly with ten percent weight to volume of acacia which, has been dispersed in sterile water.
  • the solution is refrigerated for 12 hours at 10 degrees C.
  • the solution is then removed from refrigeration. If the two phases of the coacervate system have not separated, IN hydrochloric acid is added dropwise until the two phases have separated.
  • the solution is adjusted to a pH in the range of 6.8-7.4 by the addition of sodium hydroxide. If the system is not isotonic with whole human blood, sodium chloride and/or sterile water is added to reach isotonicity.
  • the preparation is then emulsified to produce globules 2 to 9 microns in size.
  • Example 8 The procedure follows Example 8 except that after the two phase coaceryate system is prepared, the coacervate phase is separated from the equilibrium water phase by means of a separatory funnel.
  • the coacervate phase can be infused intravenously and will function as hematocrit, or it may be stored at 4 to 10 degrees C until needed.
  • the two phase coacervate system is remoyed from refrigeration and emulsified at ambient temperature by means of a colloid mill to produce globules which can range in size from 2 to 9 microns.
  • the emulsified composition can be infused at this point or stored at from 4 to 10 degrees C until needed.
  • 5% weight to volume of gelatin powder (.IEP:8.2) is mixed thoroughly with.10% weight to volume of acacia which has been dispersed in sterile water.
  • the solution is refrigerated for 24 hours at 10 degrees C. If a two phase coacervate system is not produced by the end of the refrigeration step, add IN hydrochloric acid at ambient temperature dropwise until the two phase coacervate system is produced. Adjust the pH of the system to a point within the range of 6.8 to 7.4. Add such amount of sodium chloride or sterile water as required to make it isotonic with human blood. Emulsify the two phase coacervate system to produce droplets ranging from 2 to 9 microns size.
  • Example 10 The procedures of Example 10 are followed in their entirety except that prior to emulsification, the two phases of the prepared coacervate system are separated by means of a separatory funnel. 5% weight to volume of stroma free hemoglobin is added to the coacervate phase of the two phase system. The coacervate phase can then be used as a substitute for naturally occurring hematocrit.
  • the coacervate system is then made isotonic with whole human blood by addition of the required amounts of sodium chloride and distilled water. Following this step, the solution is mixed vigorously for one hour. It is then stored at a temperature of 10 degrees C. for 72 hours. At the end of this period of storage, the solution will haye separated into two distinct layers.
  • the lower layer comprises the coacervate phase of the two phase coacervate system; the upper layer comprises the equilibrium bulk, water phase of the said system.
  • the two phases of the coacervate system can be separated or emulsified for the purposes and in the manner described previously in this disclosure. Storage of the products derived from this method should be at 4 to 10 degrees C.
  • Example 16 This procedure follows Example 16 with the following exceptions: (a) glycerol dioleate is added dropwise to the solution containing albumin, distilled water, sodium chloride, urea and lecithin, in place of di-chloromethylene and (b) prior to the emulsification step, 50 grams of stroma free hemoglobin are added and thoroughly swirled to achieve a uniform dispersion throughout the coaceryate system.
  • Example 10 Four cc. of a fresh, preparation of the sub stitute whole Blood of Example 10 was administered intravenously to each, of two rats in a third series without withdrawal of blood from either animal. One rat was sacrificed after 48 hours; seyenty two hours after infusion with substitute whole blood the second animal was sacrificed. Inspection of the tissues and red blood cells showed no pathological change or evidence of abnormal response. Clotting mechanisms appeared to be unaffected.
  • a fourth, series of tests was performed using two Nembutal anesthetized dogs. Approximately 10% of the first animal's blood was withdrawn from the femoral artery, and replaced immediately with an equal quantity of substitute whole blood of Example 1. Approximately 40% of the blood volume was withdrawn from the second dog and replaced with, an equal quantity of the substitute whole blood of Example 3. Samples of the circulating blood were withdrawn from each animal from the site of infusion at three minute intervals for fifteen minutes and at one half hour intervals for two hours thereafter. Oxygen tension measurements were determined by the IL Blood Gas Analyzer. Test results indicated an increase in PaO 2 levels over base line measurements. Carbon dioxide leyels remained within normal limits.
  • the mean arterial blood pressure in the second animal rose from 130/75 to 155/90, following infusion with substitute whole blood.
  • the mean arterial blood pressure stabilized at 130/70 in the first dog mean arterial blood pressure in the second dog stabilized at 145/75 twenty four hours after infusion.
  • mean heart rate in the first animal rose to 120. beats per minute from a base line measurement of 105.
  • Mean heart rate following infusion of the second dog rose to 155 beats per minute from a base line reading of 110. After 24 hours the mean heart rate was measured at 98.
  • the mean heart of the second animal stabilized after 24 hours at 99 beats per minute.
  • the infused substitute whole blood of Example 1 was prepared to include stroma free hemoglobin. Approximately 40% of the blood volume of this animal was withdrawn and replaced with the preparation described above. Mean blood pressure after infusion rose to 150/90 from a baseline measurement of 135/80; after 24 hours, the mean blood pressure stabilized at 140/85. Following infusion with, substitute whole blood mean heart rate rose from 110. to 145 beats per minute. After 24 hours, the mean heart rate was measured at 105. PaO 2 levels remained increased over base line measurements for approximately 9.5 minutes. Upon restoration of base line PaO 2 levels, intermittent administration of oxygen from an external source resulted in elevated oxygen tensions in this animal that persisted for approximately 6 1/2 hours. This result suggests that the claimed composition remains in the circulation, retaining its ability to transport oxygen efficiently for an appreciable period of time.
  • a sixth test involved the withdrawal of 6cc of blood from each of two common white laboratory rats and the immediate replacement with an equal amount of synthetic whole blood made in the method of Example 10.
  • Blood studies indicated elevated oxygen tensions, normal carbon dioxide levels and normal pH values. Both animals were sacrificed 72 hours. after infusion of the synthetic whole blood. Inspection of lungs, heart and other tissues reyealed no significant sign of pathological change or adverse immunological response.
  • the seventh test involved the withdrawal of 4 cc of blood from each of two common white laboratory rats, followed by the immediate replacement of 4 cc of the composition made in accordance with the method of Example 15. (Substitute for hematocrit). Blood studies indicated elevated oxygen tensions, normal carbon dioxide levels and normal pH values. Both animals were sacrificed 48 hours after infusion of the hematocrit substitute. Inspection of the lungs, heart and other tissues disclosed no significant evidence of pathological change or adverse immunological reaction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19820902044 1981-12-31 1982-05-21 Sang entier synthetique et son procede de production. Withdrawn EP0097648A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33606181A 1981-12-31 1981-12-31
US336061 1981-12-31

Publications (2)

Publication Number Publication Date
EP0097648A1 EP0097648A1 (fr) 1984-01-11
EP0097648A4 true EP0097648A4 (fr) 1984-10-18

Family

ID=23314398

Family Applications (2)

Application Number Title Priority Date Filing Date
EP82302620A Withdrawn EP0083469A3 (fr) 1981-12-31 1982-05-21 Sang complet synthétique et son procédé de préparation
EP19820902044 Withdrawn EP0097648A4 (fr) 1981-12-31 1982-05-21 Sang entier synthetique et son procede de production.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP82302620A Withdrawn EP0083469A3 (fr) 1981-12-31 1982-05-21 Sang complet synthétique et son procédé de préparation

Country Status (3)

Country Link
EP (2) EP0083469A3 (fr)
JP (1) JPS58502204A (fr)
WO (1) WO1983002228A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874742A (en) * 1981-01-05 1989-10-17 Synthetic Blood Corporation Synthetic whole blood and a process for preparing the same
EP0223906A3 (fr) * 1982-10-29 1989-02-01 Synthetic Blood Corporation Sang entier synthétique à base de gélatine et son procédé de fabrication
US4853370A (en) * 1984-04-27 1989-08-01 Synthetic Blood Corporation Substitute for human blood and a method of making the same
US4738952A (en) * 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
AU583272B2 (en) * 1984-04-27 1989-04-27 Synthetic Blood Corporation Coacervate system synthetic whole blood substitute
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1272881A (fr) * 1985-08-29 1990-08-21 John D. Sheppard Methode de pretraitement thermochimique a basse temperature pour denoyer la tourbe
CA1318589C (fr) * 1986-08-14 1993-06-01 Bernard Ecanow Systeme d'administration de medicament
WO2001012201A1 (fr) * 1999-08-12 2001-02-22 Alexandr Vilenovich Asafov Composition remplacant le plasma sanguin
WO2015157431A2 (fr) * 2014-04-08 2015-10-15 Novogy, Inc. Avantage sélectif dans la fermentation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742594A (en) * 1952-01-24 1955-12-30 Charles B Knox Gelatine Compan Preparation and purification of human serologically compatible protein derivatives for use as plasma extenders and products produced thereby
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4002739A (en) * 1975-02-18 1977-01-11 Warner-Lambert Company Soluble collagen
DE2940184A1 (de) * 1979-10-04 1981-04-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Kolloidloesung, die als blutersatz geeignet ist, und verfahren zu ihrer herstellung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742594A (en) * 1952-01-24 1955-12-30 Charles B Knox Gelatine Compan Preparation and purification of human serologically compatible protein derivatives for use as plasma extenders and products produced thereby
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4002739A (en) * 1975-02-18 1977-01-11 Warner-Lambert Company Soluble collagen
DE2940184A1 (de) * 1979-10-04 1981-04-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Kolloidloesung, die als blutersatz geeignet ist, und verfahren zu ihrer herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8302228A1 *

Also Published As

Publication number Publication date
JPS58502204A (ja) 1983-12-22
EP0083469A3 (fr) 1983-10-26
EP0097648A1 (fr) 1984-01-11
EP0083469A2 (fr) 1983-07-13
WO1983002228A1 (fr) 1983-07-07

Similar Documents

Publication Publication Date Title
US4343797A (en) Synthetic whole blood and a method of making the same
US4963526A (en) Oral insulin and a method of making the same
US4849405A (en) Oral insulin and a method of making the same
US4439424A (en) Synthetic whole blood
Vercellotti et al. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis
Leese et al. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers
Barker et al. Metabolism of tissues excised from thyroxine-injected rats
Shannon et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study
US4547490A (en) Synthetic whole blood and a method of making the same
US4423077A (en) Perfluorochemical emulsion artificial blood
WO1985005029A1 (fr) Insuline administree par voie orale et son procede de preparation
WO1983002228A1 (fr) Sang entier synthetique et son procede de production
US4558032A (en) Synthetic whole blood substitute and a method of making the same
Zhao et al. Perfluorocarbon-based oxygen carriers: What is new in 2024?
EP0124527B1 (fr) Sang entier synthetique a base de gelatine et son procede de fabrication
US4497829A (en) Process for preparing perfluorochemical emulsion artificial blood
US4738952A (en) Substitute for human blood and a method of making the same
US4596788A (en) Gelatin and lecithin based synthetic whole blood and a method of making the same
US4874742A (en) Synthetic whole blood and a process for preparing the same
AU583272B2 (en) Coacervate system synthetic whole blood substitute
CA1224144A (fr) Sang entier synthetique et procede de preparation
US4853370A (en) Substitute for human blood and a method of making the same
GOLDZIEHER Effects of interrenal function on fat metabolism and tissue respiration
DE19734279A1 (de) Wasserstoffhaltiges Medikament
CN106860446A (zh) 小儿复方氨基酸注射液19aa‑i 组合物及降低其氧含量的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH LI LU NL SE

17P Request for examination filed

Effective date: 19831222

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEOMED CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SYNTHETIC BLOOD CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19901030

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ECANOW, CHARLES S.

Inventor name: ECANOW, BERNARD